At The Anxiety Center we offer intranasal esketamine an adjunct treatment options for patient with treatment resistant depression or acute suicidal thoughts or actions. SPRAVATO® (esketamine) is an FDA approved alternative to intravenous ketamine that must be delivered at a certified SPRAVATO® treatment center. Current research indicates that it provides an important secondary approach to a significant number patients who may have exhausted more traditional means of managing treatment resistant depression and suicidal ideation. Although it is likely that there are multiple mechanisms at play, scientists believe that esketamine works by modulating the activity of the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. Although esketamine is not a treatment for everyone, it has been a life changing option for many. By coming to The Anxiety Center, you can be sure that you or your loved one will receive compassionate and effective care from experts committed to helping you achieve the best possible outcome.